Inhibitors of cyclin-dependent kinase 7 (cdk7)
AssigneeDana-Farber Cancer Institute, Inc.
InventorsNathanael Gray, Tinghu Zhang, Nicholas Paul Kwiatkowski
Life of this patent
Estimating the term…
Loading patent…
AssigneeDana-Farber Cancer Institute, Inc.
InventorsNathanael Gray, Tinghu Zhang, Nicholas Paul Kwiatkowski
Estimating the term…
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
1-86. (canceled)
A method of treating a proliferative disease in a subject in need thereof, the method comprising:
(canceled)
90-92. (canceled)
94-98. (canceled)
100-118. (canceled)
Dependencies are inferred from the claim text.